|1.||Ahn, Dong K: 2 articles (10/2008 - 10/2006)|
|2.||Park, Hyo S: 2 articles (10/2008 - 10/2006)|
|3.||Bae, Yong C: 2 articles (10/2008 - 10/2006)|
|4.||Kim, Yang In: 1 article (05/2013)|
|5.||Han, Hee Chul: 1 article (05/2013)|
|6.||Lee, Kyu Sang: 1 article (05/2013)|
|7.||Park, Eui Ho: 1 article (05/2013)|
|8.||Cho, Hwi-Young: 1 article (05/2013)|
|9.||Kamei, Chiaki: 1 article (01/2011)|
|10.||Fukuhara, Satoko: 1 article (01/2011)|
05/10/2013 - "In the maintenance phase, APDC at all doses (10, 100 and 500μM) and 100 and 500μM L-AP4 significantly counteracted the reduction in weight load, and APDC and L-AP4 at all doses (10, 100 and 500μM) inhibited mechanical hyperalgesia. "
05/10/2013 - "Similarly, 100 and 500μM APDC and 500μM L-AP4 significantly reduced mechanical hyperalgesia during the induction phase. "
04/01/2010 - "We determined the effects of the group I mGluR antagonist AIDA, the group II mGluR agonist ADPC, and the group III mGluR agonist L-AP4 on BV-induced PSN, mechanical hyperalgesia, and inflammatory swelling. "
10/01/2006 - "Intracisternal administration of APDC, a group II mGluR agonist, or L-AP4, a group III mGluR agonist, reduced both IL-1beta-induced mechanical allodynia and mirror-image mechanical allodynia. "
01/01/2005 - "An intrathecal (5-30 microg) L-AP4 dose-dependently attenuated allodynia in nerve-injured rats but had no antinociceptive effect in normal rats. "
01/01/2006 - "L-AP4 improved the acquisition, consolidation and retrieval processes as well as the hypoxia-induced consolidation deficit in the passive avoidance test. "
01/01/2006 - "In a group of rats that had undergone hypoxia, joint administration of baclofen and L-AP4 improved retrieval as well as enhanced the effect of baclofen and L-AP4 vs. their respective group without hypoxia. "
01/01/2006 - "It is concluded that baclofen and L-AP4 may cooperate in the consolidation process in rats without hypoxia and in retrieval of passive avoidance in animals that had undergone hypoxia. "
01/01/2006 - "L-AP4 given alone or with baclofen produced an anxiogenic-like effect in rats without hypoxia but produced an anxiolytic-like effect in those that had undergone hypoxia. "
01/01/2006 - "We studied the behavioral effects of baclofen on hypoxia-induced amnesia and the role of L-AP4 in these processes. "
01/01/2011 - "In addition, simultaneous use of AIDA and (2R,4R)-APDC or L-AP4 caused more potent inhibition of seizure activities. "
01/01/2011 - "Intracerebroventricular injection of AIDA and L-AP4 showed significant inhibitory effects on pentetrazol-induced kindled seizures. "
07/28/2009 - "The group III mGluR agonist L-AP4 [L-(+)-2-amino-4-phosphonobutyric acid at 100 nmol, i.c.v.] did not significantly affect the kindling of seizures in comparison to control rats, although there was acceleration of the process as compared to CPPG treated animals. "
05/02/1997 - "L-AP4 inhibited epileptogenesis at 10 nmol in 0.5 microl buffer, by preventing the increase in both seizure score and afterdischarge duration. "
02/02/1996 - "Intra-AM injection of 1S,3R-ACPD (40 or 200 nmol) or L-AP4 (200 nmol) resulted in a delayed and marked suppression of kindled seizures, 3 days after 40 nmol of 1S,3R-ACPD, 1 day after 200 nmol of 1S,3R-ACPD, and from 1 to 3 days after 200 nmol of L-AP4. "
05/10/2013 - "During the induction phase of arthritic pain, a significant recovery of reduced weight load occurred after the administration of 500μM APDC ((2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate; group II agonist) and 100 and 500μM L-AP4 (l-2-amino-4-phosphonobutylate; group III agonist). "
10/15/2008 - "Group II or III mGluRs agonists were administered intracisternally 10 min after intracisternal administration of WIN 55,212-2. Neither 100 nmol APDC, a group II mGluRs agonist, nor L-AP4, a group III mGluR agonist, altered nociceptive behavior when given alone but significantly inhibited the formalin-induced nociceptive behavior in the presence of a sub-threshold dose ( 3microg) of WIN 55,212-2. The ED50 value of APDC or L-AP4 was significantly reduced upon co-treatment with WIN 55,212-2 than in the vehicle-treated group, highlighting the important therapeutic potential of the combined administration of group II or III mGluR agonists with cannabinoids to effectively treat inflammatory pain associated with the TMJ. "
|5.||Ganglion Cysts (Ganglion)
|2.||6-Cyano-7-nitroquinoxaline-2,3-dione (6 Cyano 7 nitroquinoxaline 2,3 dione)
|6.||gamma-glutamylaminomethylsulfonic acid (GAMS)
|9.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|10.||Glutamate Receptors (Glutamate Receptor)